TORL Biotherapeutics

A clinical-stage biopharmaceutical company advancing the development of new biologics for cancer treatment. TORL-Bio was founded in 2018 and is focused on the development of novel antibody-based therapeutics for cancer patients. TORL has currently 3 therapeutics in Ph1 clinical trials in indications such as NSCLC, gastric, pancreatic and ovarian cancers.